Focus;
5-10
ASUR best overall chart this morning
| Day's Range: | 4.92 - 5.64 |
|---|---|
| 52wk Range: | 1.51 - 6.35 |
| Volume: | 97,982 |
| Avg Vol (3m): | 13,982 |
2-3
Recall DCTH pickup yesterday on building FDA anticipation....Notice rebuilding as the day progresses / strength in general.....
Recall details of article: Delcath Systems, Inc (DCTH)
Drug Name: CHEMOSAT; NDA Filing Date: mid-August 2012
Delcath Systems is a development-stage specialty pharmaceutical and medical device company focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system.
On May 8, 2012, Mr. Eamonn P. Hobbs, President and CEO of Delcath said:
Delcath Systems has a market cap of $76.74, and is currently trading around $1.53, with a 52-week range of $1.40 to $6.64.
(For a look at six biotech names we thought had huge potential in July, click here.)
Some of the data is sourced from Google Finance, Yahoo Finance, Fidelity and investors site.
Disclosure: I have no positions in any stocks mentioned
Drug Name: CHEMOSAT; NDA Filing Date: mid-August 2012
Delcath Systems is a development-stage specialty pharmaceutical and medical device company focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system.
On May 8, 2012, Mr. Eamonn P. Hobbs, President and CEO of Delcath said:
Following the anticipated NDA submission in mid-August, Delcath expects monthly cash expenses to decrease to $3 million to $4 million for the remainder of 2012. The Company expects revenue from CHEMOSAT sales in the second half of the year will partially offset cash expenditures.
We are in the final stages of completing our New Drug Application (NDA) submission for filing with the FDA for CHEMOSAT. Safety data collection and database migration is complete, the clinical sites have been notified that we will lock the databases on May 25th, and we are confident of submitting our NDA in mid-August.
Delcath Systems has a market cap of $76.74, and is currently trading around $1.53, with a 52-week range of $1.40 to $6.64.
(For a look at six biotech names we thought had huge potential in July, click here.)
Some of the data is sourced from Google Finance, Yahoo Finance, Fidelity and investors site.
Disclosure: I have no positions in any stocks mentioned
Pennies:
Prior we discussed IWEB ongoing support at .12......Reminder on insider purchases earlier in the week and constant reminding on surge in orders.......Continue to debate for fair amount of risk taken out under .13 / repeat back to .18.........We keep reflecting on how IWEB stands to benefit directly from govt mandate to to switch all storage to clould based systems and the fact they are already landing several public sector contracts in 2012....
| IWEB | 11:31am EDT | 0.13 |  0.0010 | 0.78% | 65,350 |
| IceWEB Executives Purchase Additional Stock as a Sign of Continued Confidence in Company Marketwire10:43am EDT | ||
"Since joining IceWEB's board in 2005, I've seen a company with tremendous potential make continuous progress in the pervasive and rapidly growing market for data storage solutions, especially in the past six months," said Hal Compton, Interim CEO at IceWEB. "Since increasing my involvement with IceWEB as CEO last month, my perspective of the company's current strength and potential has only grown stronger. .....
Headquartered just outside of Washington, D.C., IceWEB manufactures award-winning, high performance unified data storage products with enterprise storage management capabilities at a fraction of the price of traditional providers. Through thin provisioning, target deduplication and inline compression, IceWEB's unified storage arrays enable standardization, consolidation and optimized storage utilization for virtual and cloud environments, saving up to 90% of storage costs, while reducing space, power and cooling requirements and simplifying storage management.
http://www.nbtequitiesresearch.com/company/iceweb-iweb-2/report/iceweb-iweb-the-strong-case-for-big-top-line-and-bottom-line-growth-in-2012-2013
As we talked about in our original report, IWEB has made significant advancements in key areas of the business over the past six months.....IceWEB has received a surge in orders since the beginning of 2012, including a Global 50 electronics manufacturer, several federal, state and local government procurements; and a spike in mid-market commercial customers ........IceWEB channel partner commitment has strengthened, with renewed interest from channel partners such as DataSpan, CloudFront Group, DST, Navigate Storage, AR Consultant Group, Promark Technology Solutions, and numerous others due to rising demand and bolstered pipelines ........reported its second consecutive quarter of double-digit revenue growth earlier this month, with a 49% topline increase quarter-over-quarter.
Observing how the dust settles after recent tripling with XCLL.....Yahoo unable to bring up 5day chart....run started around .13 earlier in week....
No comments:
Post a Comment